Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 42.9% during mid-day trading on Tuesday . The stock traded as high as C$0.11 and last traded at C$0.10. 340,639 shares changed hands during trading, an increase of 259% from the average session volume of 94,936 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The company has a market cap of C$10.45 million, a P/E ratio of -6.00 and a beta of 0.20. The stock has a 50-day moving average of C$0.08 and a 200 day moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- There Are Different Types of Stock To Invest In
- Why These 3 Stocks Are Set to Gain From a Bond Market Shift
- 3 Healthcare Dividend Stocks to Buy
- 65 Million NFL Views Propel Netflix Toward Long-Term Growth
- 3 Warren Buffett Stocks to Buy Now
- Uber Stock Gears Up for a Massive Growth Ride
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
